Is Biotech Finally In A Bubble? | Seeking AlphaDoctoRx has written an outstanding article on the biotech sector. I agree 100% with the doctor that biotech stocks are worth a good portion of your portfolio. I own XBI, the small cap biotech ETF, and BIB, the 2x leveraged ETF for large cap biotech stocks. These two stocks have far outperformed […]
Since the beginning of this year the markets have primarily treaded water. The primary support for the bulls has been continued acknowledgement by the Fed on an inability to remove accommodative policy by raising interest rates. (Which should make you question what happens the first time they do.) The bears have been feasting on weak economic data and deteriorating fundamentals. […]
Submitted by Lance Roberts via STA Wealth Management,Since the beginning of this year the markets have primarily treaded water. The primary support for the bulls has been continued acknowledgement by the Fed on an inability to remove accommodative policy by raising interest rates. (Which should make you question what happens the first time they do.) The bears have been feasting […]
Do not worry, “it’s contained.” From The FOMC Statement, Gold is 1st, Bonds 2nd, and Stocks 3rd…
WEAK CLOSE; Trannies remain the big squeeze post-FOMC winner but Dow is the laggard…
On the week, however, Trannies lagged and ended the week red (down 4 of the last 5 weeks) as Small Caps (dominated by Biotech ‘no brainers’) led the pop…
Biotechs were up […]
Do not worry… “it’s contained”From The FOMC Statement, Gold is 1st, Bonds 2nd, and Stocks 3rd…and on the week the same picture…WEAK CLOSE…Trannies remain the big squeeze post-FOMC winner but Dow is the laggard…On the week, however, Trannies lagged and ended the week red (down 4 of the last 5 weeks) as Small Caps (dominated by Biotech ‘no brainers’) led […]
While the stocks are not cheap, they’re not expensive, he added. What investors are paying for is high quality growth and high quality earnings.Read MoreCramer: Secret pattern to unlocking biotech richesIn fact, he thinks people have underappreciated biotech’s “fantastic” margins, noting that the companies now have 50 to 70 percent operating margins and “tons of real cash flow.””These are real […]
Continue reading:
Otmane Adamske – Listen To The Biotech CEO Interviews – Cramer’s Mad Money (6/18/15) | Seeking Alpha
See which stocks are being affected by Social Media
[…]
These Promising Cancer Therapies Are a Biotech Stocks “Triple Play”Companies / BioTechJun 19, 2015 – 03:04 PM GMTBy: Money_MorningErnie Tremblay writes: On Jan. 7, 2015, CytRX Corp. (NASDAQ: CYTR) announced positive results from a study of its experimental brain cancer drug, aldoxorubicin, and the company’s stock immediately jumped 15.8%. Then, over the next four months, it nearly doubled.Over the months […]
Activist investor Elliott set sights on Asia’s family-run firms by BusinessInsider.com : Thursday 09:02:30 CTCategories: markets, streamBy Denny Thomas and Svea Herbst-BaylissHONG KONG/NEW YORK (Reuters) – U.S. billionaire Paul Singer appears to have paved the way for activist investors to fight for shareholders’ rights where few hedge funds have ventured: Asia’s biggest family-run firms.In the past few months, Singer’s $26 […]
Biotech gains attainable?
Mad Money’s Jim Cramer picked up on a biotech pattern that could benefit your portfolio.
Jim Cramer has picked up on a pattern when it comes to biotech stocks that could change the game for an investor’s portfolio—listen to the darned CEO interviews.In fact, Cramer would argue that the biotech group has gone from being hit or miss to […]
